R Komaki

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239
    Ritsuko Komaki
    Department of Radiation Oncology, Unit 97, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 83:e531-6. 2012
  2. ncbi Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer
    Arya Amini
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Radiat Oncol 7:33. 2012
  3. ncbi Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer
    Erik P Sulman
    Department of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA
    Radiat Oncol 4:5. 2009
  4. ncbi TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy
    Xiaoxiang Guan
    Department of Epidemiology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    BMC Cancer 11:447. 2011
  5. ncbi Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy
    Xiaoxiang Guan
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    BMC Cancer 10:431. 2010
  6. ncbi Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04
    R Komaki
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 97, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:548-57. 2002
  7. ncbi Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12
    Ritsuko Komaki
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 62:342-50. 2005
  8. ncbi Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Semin Oncol 32:S92-8. 2005
  9. ncbi The management of superior sulcus tumors
    R Komaki
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Semin Surg Oncol 18:152-64. 2000
  10. ncbi Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1369-77. 2004

Detail Information

Publications147 found, 100 shown here

  1. ncbi Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239
    Ritsuko Komaki
    Department of Radiation Oncology, Unit 97, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 83:e531-6. 2012
    ....
  2. ncbi Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer
    Arya Amini
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Radiat Oncol 7:33. 2012
    ....
  3. ncbi Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer
    Erik P Sulman
    Department of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA
    Radiat Oncol 4:5. 2009
    ....
  4. ncbi TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy
    Xiaoxiang Guan
    Department of Epidemiology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    BMC Cancer 11:447. 2011
    ..abstract:..
  5. ncbi Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy
    Xiaoxiang Guan
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    BMC Cancer 10:431. 2010
    ..We hypothesized that VEGF polymorphisms may affect survival outcomes among locally advanced non-small cell lung cancer (LA-NSCLC) patients...
  6. ncbi Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04
    R Komaki
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 97, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:548-57. 2002
    ..The Radiation Therapy Oncology Group (RTOG) Study 92-04 was a randomized Phase II study designed to evaluate further the toxicity and efficacy of 2 different strategies of chemoradiation evaluated in 2 prior RTOG Phase II studies...
  7. ncbi Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12
    Ritsuko Komaki
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 62:342-50. 2005
    ..The purpose of RTOG 97-12 was to determine the maximum tolerated dose (MTD) of thoracic radiation therapy (RT) with concurrent chemotherapy for patients with limited-stage small-cell lung cancer...
  8. ncbi Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Semin Oncol 32:S92-8. 2005
    ..AMF reduced the incidence of grade 3/4 lung fibrosis among higher MS. These data suggest that MS might help identify subgroups of patients who could receive more benefit from AMF with respect to lung damage...
  9. ncbi The management of superior sulcus tumors
    R Komaki
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Semin Surg Oncol 18:152-64. 2000
    ..Whenever possible, to enhance the patient's quality of life, surgery should be considered to improve function and relieve pain...
  10. ncbi Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1369-77. 2004
    ..To determine the ability of amifostine to reduce the severity and/or incidence of the acute toxicities of concurrent chemotherapy and radiotherapy (RT) for non-small-cell lung cancer...
  11. ncbi Target definition and contouring in carcinoma of the lung and esophagus
    Ritsuko Komaki
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Rays 28:225-36. 2003
    ..There we review the normal anatomy, diagnostic methods, and tumor delineation of cancer of the lung and esophagus...
  12. ncbi A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction
    J A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:279-86. 2001
    ..After chemoradiotherapy, patients underwent surgery. The feasibility of this approach, curative resection rates, patient survival, and patterns of failure were assessed...
  13. ncbi The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 45:1143-9. 1999
    ..The purpose of this study is to analyze the impact of age, histology, Karnofsky performance status (KPS), and specific toxicities on the median survival time (MST) and quality-adjusted survival (QTime) for each treatment strategy...
  14. ncbi A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report
    J S Lee
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 42:479-86. 1998
    ....
  15. ncbi The relationship between local dose and loss of function for irradiated lung
    Ramesh Gopal
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 56:106-13. 2003
    ..The very low (13 Gy) threshold for deterioration of DL(CO) suggests that it is better to treat a little normal lung to a high dose than to treat a lot to a low dose...
  16. ncbi Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival
    M Werner-Wasik
    Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 48:1475-82. 2000
    ..This analysis was undertaken to identify these characteristics in a large cooperative group patient population, as well as to define subgroups of the population with differing outcomes...
  17. ncbi Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12
    B Glisson
    University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 18:2990-5. 2000
    ....
  18. ncbi Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01
    Benjamin Movsas
    Department of Radiation Oncology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Clin Oncol 23:2145-54. 2005
    ..To test the ability of the cytoprotectant, amifostine, to reduce chemoradiotherapy-induced esophagitis and evaluate its influence on quality of life (QOL) and swallowing symptoms...
  19. ncbi Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer
    R Komaki
    Department of Radiotherapy, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 36:601-5. 1996
    ....
  20. ncbi Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung canc
    Xiaodong Zhang
    Division of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 77:357-66. 2010
    ....
  21. ncbi Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus
    Pooja R Rohatgi
    Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1349-55. 2005
    ..Future investigations should focus on reducing the proportion of residual carcinoma and metastatic disease progression in patients with esophageal carcinoma...
  22. ncbi Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705
    Jeffrey D Bradley
    Department of Radiation Oncology, Washington University Medical Center, 4921 Parkview Place LL, Mail Stop 90 38 635, St Louis, MO 63110, USA
    J Clin Oncol 23:3480-7. 2005
    ....
  23. ncbi Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction
    E D Tetzlaff
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77005 4341, USA
    Dis Esophagus 21:575-81. 2008
    ..Active research to prevent and treat TEEs is needed to improve survival of patients with localized gastroesophageal cancer...
  24. ncbi Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials
    J D Cox
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 43:505-9. 1999
    ..To evaluate the influence of cell type within non-small cell carcinoma of lung (NSCCL) on failure patterns when chemotherapy (CT) is combined with radiation therapy (RT)...
  25. ncbi Correlation between lung fibrosis and radiation therapy dose after concurrent radiation therapy and chemotherapy for limited small cell lung cancer
    I I Rosen
    Department of Radiation Physics, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 94, Houston, TX 77030, USA
    Radiology 221:614-22. 2001
    ..To evaluate the relationship between physician-identified radiographic fibrosis, lung tissue physical density change, and radiation dose after concurrent radiation therapy and chemotherapy for limited small cell lung cancer...
  26. ncbi Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results
    R Komaki
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Semin Radiat Oncol 12:46-9. 2002
    ..Only 1 patient discontinued treatment because of hypotension. These preliminary results showed that amifostine significantly reduced acute severe esophagitis and pneumonitis. Further observation is required to assess long-term efficacy...
  27. ncbi Imaging of non-small cell lung cancer of the superior sulcus: part 2: initial staging and assessment of resectability and therapeutic response
    John F Bruzzi
    Division of Diagnostic Imaging, Department of Radiation Oncology, M D Anderson Cancer Center, Houston, Tex, USA
    Radiographics 28:561-72. 2008
    ..However, imaging has only limited usefulness for evaluating the response of a tumor to induction therapy and detecting local recurrence, and surgical biopsy often is necessary to verify the results of therapy...
  28. ncbi Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma
    David Hong
    Department of GI Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1620-6. 2005
    ..Baseline NPA (> 1), reflecting the regional nodal metastases, is an independent predictor of OS. Baseline PET may become a useful stratification factor in randomized trials and for individualizing therapy...
  29. ncbi Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters
    Hoon K Lee
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 57:1317-22. 2003
    ..Radiotherapy techniques that decrease the volume of lung receiving low radiation doses may significantly reduce the risk of this potentially life-threatening complication...
  30. ncbi Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation
    P Cen
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Dis Esophagus 22:32-41. 2009
    ..Our intriguing findings need confirmation followed by in-depth molecular study to explain these differences...
  31. ncbi Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome
    P R Rohatgi
    Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas 77030, USA
    Dis Esophagus 19:152-7. 2006
    ..The reasons for these differences remain unclear and further expansion of these observations and study of biologic differences that might exist are warranted...
  32. ncbi Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery
    N A Taylor
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 56:616-25. 2003
    ..Significantly improved survival was observed in all patients who responded to induction chemotherapy compared with those with stable or progressive disease...
  33. ncbi Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo
    K A Mason
    Department of Experimental Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 5:4191-8. 1999
    ....
  34. ncbi Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer
    Xiaochun Zhang
    Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:6657-68. 2005
    ..Ad/TRAIL-F/RGD may improve the therapeutic ratio of radiotherapy in NSCLC...
  35. ncbi Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma
    Jeffrey Bradley
    Department of Radiation Oncology, Washington University Siteman Cancer Center, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 61:318-28. 2005
    ..To evaluate prospectively the acute and late morbidities from a multiinstitutional three-dimensional radiotherapy dose-escalation study for inoperable non-small-cell lung cancer...
  36. ncbi Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy
    Xiong Wei
    Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:100-7. 2006
    ..CONCLUSIONS: The risk of AE in the NSCLC patients treated with CCT and 3D-CRT was primarily determined by dosimetric factors. These factors should be carefully considered during treatment planning to minimize the incidence of AE...
  37. ncbi Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer
    Jin S Lee
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 52:362-70. 2002
    ..We conducted this retrospective cohort study to examine its impact on the outcome of patients undergoing combined chemoradiation therapy for the treatment of locally advanced inoperable non-small-cell lung cancer...
  38. ncbi Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer
    Xiaodong Zhang
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:278-87. 2008
    ....
  39. ncbi Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer
    R Komaki
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 40:787-96. 1998
    ....
  40. ncbi [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer
    Ryohei Sasaki
    Department of Radiation Oncology, Unit 97, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:1136-43. 2005
    ..03) and DFS (P = .001). CONCLUSION: The SUV of the primary tumor was the strongest prognostic factor among the patients treated by curative surgery or radiotherapy...
  41. ncbi Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation
    Heta Javeri
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:624-30. 2009
    ..The authors evaluated initial standardized unit value (iSUV) of 18F-fluoro-2-deoxy-D-glucose positron emission tomography and its association with overall survival and the degree of pathologic response after surgery...
  42. ncbi Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer
    Hasan Murshed
    Division of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1258-67. 2004
    ..The dosimetric benefits of IMRT for advanced-stage non-small-cell lung cancer must be evaluated further in clinical trials...
  43. ncbi Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer
    Faye M Johnson
    Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, USA
    Clin Lung Cancer 5:40-5. 2003
    ..With the exception of the 2 deaths, the therapy was well tolerated and active. Phase II evaluation of the regimen in patients with extensive-stage SCLC is ongoing...
  44. ncbi Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer
    S G Swisher
    Departments of Thoracic and Cardiovascular Surgery, Medical Informatics, Gastrointestinal Oncology, and Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Thorac Cardiovasc Surg 119:1126-32. 2000
    ..We sought to evaluate the effect of operative volume, hospital size, and cancer specialization on morbidity, mortality, and hospital use after esophagectomy for cancer...
  45. ncbi Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function
    C W Stevens
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 51:62-8. 2001
    ..To determine whether superior-inferior lung tumor motion is predictable by tumor size or location, or pulmonary function test results...
  46. ncbi Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy
    Hitoshi Ikushima
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Radiat Res (Tokyo) 51:465-71. 2010
    ..In conclusion, assessment of predictive value of SUV(max) for NSCLC requires consideration of primary tumor size, and the evidence is not sufficient to suggest that FDG uptake in a primary NSCLC provides prognostic information...
  47. ncbi Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy
    Sue S Yom
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:94-102. 2007
    ..To investigate the rate of high-grade treatment-related pneumonitis (TRP) in patients with advanced non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT)...
  48. ncbi A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer
    Charles Lu
    Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2085-91. 2003
    ..The outcome of a recently closed Cancer and Leukemia Group B Phase II study of similar design (CLB-39808) should help determine whether or not this approach warrants testing in a randomized setting...
  49. ncbi Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation
    David R Grosshans
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:589-95. 2008
    ..Neuropsychologic testing was prospectively conducted before and after PCI to evaluate its effects on cognitive function in patients with SCLC...
  50. ncbi Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation
    Patrick Kelly
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 78:1387-93. 2010
    ..In this study, we retrospectively reviewed outcomes after SBRT for recurrent disease among patients previously given radiation therapy to the chest...
  51. ncbi Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:779-85. 2007
    ..To retrospectively compare outcomes for patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) treated at our institution with concurrent chemoradiation with or without induction chemotherapy...
  52. ncbi Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma
    Anesa Ahamad
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 55:768-75. 2003
    ..In light of patients' tolerance to post-EPP IMRT, it may be feasible to incorporate systemic therapy, including novel biologic therapies into the treatment regimen...
  53. ncbi Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography
    Brian P Yaremko
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 70:145-53. 2008
    ..To investigate the motion characteristics of distal esophagus cancer primary tumors using four-dimensional computed tomography (4D CT)...
  54. ncbi Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer
    Ramesh Gopal
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 56:114-20. 2003
    ..CONCLUSIONS: The addition of chemotherapy to RT significantly exacerbates the post-RT decrease in TLC and DLCO. The greatest decrease in DLCO occurs in patients treated with concurrent chemoradiation...
  55. ncbi Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest
    Anesa Ahamad
    Department of Radiation Oncology, Section of Thoracic Molecular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:476-84. 2003
    ..As local control improves, systemic metastases become more common, and it may be appropriate to add novel agents to further improve the therapeutic ratio...
  56. ncbi Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer
    Shu-Lian Wang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    World J Gastroenterol 12:5501-8. 2006
    ..However, local and distant recurrence and toxicity remain to be a problem. Innovative approaches are needed to improve the outcome...
  57. ncbi Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer
    Faye M Johnson
    Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 17:17-21. 2003
    ..Patients generally tolerated the weekly alternating chemotherapy with irinotecan/cisplatin and etoposide/cisplatin well, and this combination possessed significant antitumor activity in small-cell lung cancer...
  58. ncbi Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy
    L Christine Fang
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:108-16. 2006
    ..CONCLUSIONS: This study demonstrates that 3D conformal radiotherapy improves outcomes in patients with medically inoperable Stage I NSCLC compared with 2D treatment and is an acceptable treatment for this group of patients...
  59. ncbi Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance
    Brian P Yaremko
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:562-71. 2007
    ....
  60. ncbi Dosimetric benefits of respiratory gating: a preliminary study
    Laura E Butler
    Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Appl Clin Med Phys 5:16-24. 2004
    ..Respiratory gating of thoracic radiation treatments can often improve the quality of the treatment plan, but it may not be possible to determine which patients may benefit from gating prior to performing the actual treatment planning...
  61. ncbi 4D Proton treatment planning strategy for mobile lung tumors
    Yixiu Kang
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 67:906-14. 2007
    ..To investigate strategies for designing compensator-based 3D proton treatment plans for mobile lung tumors using four-dimensional computed tomography (4DCT) images...
  62. ncbi Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging
    Jeremy J Erasmus
    Department of Diagnostic Imaging, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:478-86. 2006
    ..We evaluated the use of integrated computed tomography (CT)-PET among patients with esophageal cancer being considered for resection after CRT...
  63. ncbi Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer
    Ritsuko Komaki
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 31:47-53. 2004
    ..Here we discuss the rationale for using selective COX-2 inhibitors and describe current clinical protocols and the initial findings...
  64. ncbi Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 73:119-27. 2009
    ....
  65. ncbi Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases
    Ivan Milas
    Departments of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:1070-6. 2003
    ..These three biomarkers cannot be used to predict brain metastasis. Studies of other biomarkers are under way in an effort to predict brain metastasis among patients with NSCLC...
  66. ncbi Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer
    Zhouguang Hui
    Department of Radiation Phyiscs, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 72:1385-95. 2008
    ..Proton doses are sensitive to intra- and interfractional anatomic changes. We analyzed the effects of interfractional anatomic changes in doses to lung tumors treated with proton therapy...
  67. ncbi Imaging of non-small cell lung cancer of the superior sulcus: part 1: anatomy, clinical manifestations, and management
    John F Bruzzi
    Division of Diagnostic Imaging, Department of Radiation Oncology, M D Anderson Cancer Center, Houston, Tex, USA
    Radiographics 28:551-60; quiz 620. 2008
    ..Familiarity with the complex anatomy of the superior pulmonary sulcus is particularly crucial for determining the local-regional extension of a tumor and the most appropriate surgical approach...
  68. ncbi INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy
    Bruce D Minsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:1167-74. 2002
    ..To compare the local/regional control, survival, and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the treatment of patients with esophageal cancer...
  69. ncbi Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort
    Grace L Smith
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Int J Radiat Oncol Biol Phys 74:482-9. 2009
    ..Optimal management of elderly patients with nonmetastatic esophageal cancer is unclear. Outcomes data after locoregional treatment are lacking for this group...
  70. ncbi Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801
    Benjamin Movsas
    Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI 48202, USA
    J Clin Oncol 27:5816-22. 2009
    ..To determine the added value of quality of life (QOL) as a prognostic factor for overall survival (OS) in patients with locally advanced non-small-cell lung cancer (NSCLC) treated on Radiation Therapy Oncology Group RTOG-9801...
  71. ncbi Combined treatment for limited small cell lung cancer
    Ritsuko Komaki
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, TX 77030, USA
    Semin Oncol 30:56-70. 2003
    ..It is important to select patients with limited SCLC who are able to tolerate concurrent chemotherapy and accelerated TRT...
  72. ncbi Management of unresectable non-small cell carcinoma of the lung (NSCLC)
    J D Cox
    Department of Radiation Oncology, M. D. Anderson Cancer Center, Houston, TX, USA
    Lung Cancer 42:S15-6. 2003
  73. ncbi Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen
    Q Yang
    Department of Pathology, The University of Texas M.D, Anderson Cancer Center, Houston, Texas, USA
    Dis Esophagus 17:38-43. 2004
    ..The utility of PCEB in predicting residual cancer in the lymph nodes needs to be explored further along with molecular predictors of response to preoperative therapy...
  74. ncbi The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation
    Kim L Wang
    Departments of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1467-74. 2006
    ..The presence of NE differentiation in residual tumor was associated with poor survival after preoperative neoadjuvant therapy...
  75. ncbi The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials
    Farzan Siddiqui
    Department of Radiation Oncology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    J Thorac Oncol 5:631-9. 2010
    ..A meta-analysis was conducted to determine the influence of gender, race, and marital status on overall survival (OS) in Radiation Therapy Oncology Group nonoperative non-small cell lung cancer trials...
  76. ncbi Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer
    Yoshiyuki Shioyama
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:1349-58. 2007
    ..To assess quantitatively the impact of incorporating functional lung imaging into intensity-modulated radiation therapy planning for locally advanced non-small cell lung cancer (NSCLC)...
  77. ncbi Validation of a model-based segmentation approach to propagating normal anatomic regions of interest through the 10 phases of respiration
    Muthuveni Ezhil
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:900-6. 2008
    ....
  78. ncbi Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy
    Xiong Wei
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 70:707-14. 2008
    ..To identify clinical and dosimetric factors influencing the risk of pericardial effusion (PCE) in patients with inoperable esophageal cancer treated with definitive concurrent chemotherapy and radiation therapy (RT)...
  79. ncbi Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer
    Keiko Shibuya
    Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:1534-43. 2007
    ....
  80. ncbi Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications
    Alexander Chi
    Department of Radiation Oncology, University of Arizona, 1501 N Campbell Ave, Tucson, AZ 85724, USA
    Radiother Oncol 94:1-11. 2010
    ..To analyze the patterns of failure, the toxicity profile, and the factors influencing efficacy of stereotactic body radiation (SBRT) for early-stage non-small-cell lung cancer (NSCLC)...
  81. ncbi Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response
    Jennifer Sims-Mourtada
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:6565-72. 2006
    ..CONCLUSIONS: These results suggest that activation of the Hh pathway may promote tumor repopulation after chemoradiotherapy and contribute to chemoradiation resistance in esophageal cancers...
  82. ncbi Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience
    Mitchell Machtay
    Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 63:667-71. 2005
    ..Further study of novel radiation-chemotherapy dose/fractionation regimens is warranted...
  83. ncbi Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection
    Noah A Taylor
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:204-12. 2004
    ..To improve survival, however, newer systemic agents that reduce and control distant metastasis are required...
  84. ncbi Heterogeneous planning for homogeneous protocols
    Chris Brooks
    Radiation Physics, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Med Dosim 29:80-4. 2004
    ..This paper describes a procedure that has been developed to satisfy the requirements of a homogeneous protocol, such as RTOG 98-01 (A Phase III Study of Amifostine mucosal protection), while maintaining accuracy in treatment planning...
  85. ncbi Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response
    Pooja Rohatgi
    Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:2365-72. 2005
    ..Chemoradiotherapy as primary therapy for patients with Stage I esophageal carcinoma warrants investigation as a means to preserve their esophagus...
  86. ncbi Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer
    J A Ajani
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
    Ann Oncol 23:2638-42. 2012
    ..We hypothesized that a model based on clinical parameters could predict pathCR with a high (≥60%) probability...
  87. ncbi Gene therapy approaches for the management of non-small cell lung cancer
    J A Roth
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 28:50-6. 2001
    ..This review examines several important issues in cancer gene therapy in general and the most recent achievements in gene therapy for non-small cell lung cancer...
  88. ncbi Biology-based combined-modality radiotherapy: workshop report
    K A Mason
    Department of Experimental Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 50:1079-89. 2001
    ..The purpose of this workshop summary is to provide an overview of preclinical and clinical data on combined-modality radiotherapy...
  89. ncbi Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer
    Stephen G Swisher
    Department of Thoracic Surgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Thorac Surg 78:1152-60; discussion 1152-60. 2004
    ....
  90. ncbi Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus
    Dipen M Maru
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 32:1404-11. 2008
    ..031). There was no difference in prognosis between patients with large-cell NEC and those with small-cell neuroendocrine carcinoma. Esophageal NEC is an aggressive tumor, and patients with mix NEC have better outcome...
  91. ncbi Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:2347-54. 2004
    ..Patients with localized esophageal carcinoma often develop locoregional and distant disease recurrence. The current study investigated the outcome of a new chemotherapy combination as induction therapy before chemoradiotherapy...
  92. ncbi Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4551-6. 2008
    ..The primary end point was to assess whether any approach would achieve a >or= 77.5% 1-year survival rate, surpassing the historical 66% rate from the Radiation Therapy Oncology Group (RTOG) protocol 9405...
  93. ncbi Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:967-71. 2008
    ..To evaluate the efficacy and adverse effects of image-guided stereotactic body radiation therapy (SBRT) in centrally/superiorly located non-small-cell lung cancer (NSCLC)...
  94. ncbi Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients
    Zhongxing Liao
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 60:1484-93. 2004
    ..To evaluate the effect of surgical resection on the outcome of patients with clinical Stage II or III cancer of the esophagus treated with concurrent chemoradiotherapy...
  95. ncbi Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, Thoracic Cardiovascular Surgery, Radiation Therapy, Pathology, Radiology, and Biostatistics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Lung Cancer 44:369-79. 2004
    ..To evaluate tumor resectability after induction chemotherapy and to determine disease-free and overall survival rates of patients with locally advanced unresectable thymoma that received a multimodal treatment regimen...
  96. ncbi Uncertainties in physical and biological targeting with radiation therapy
    James D Cox
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Rays 28:211-5. 2003
    ..Molecular therapeutic agents enhance the effects of ionizing radiations in murine systems. Clinical trials combining molecular targeting agents with conformal radiation therapy are being initiated...
  97. ncbi Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part II-margin reduction of internal target volume
    H Helen Liu
    Division of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 60:1473-83. 2004
    ....
  98. ncbi Analysis of radiation pneumonitis risk using a generalized Lyman model
    Susan L Tucker
    Department of Bioinformatics and Computational Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 72:568-74. 2008
    ....
  99. ncbi Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer
    H Helen Liu
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1268-79. 2004
    ....
  100. ncbi Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808
    Mary Frances McAleer
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 76:802-8. 2010
    ..Concurrent chemoradiotherapy (CCRT) is superior to ICT followed by RT. The question arises whether ICT response predicts the outcome of patients subsequently treated with CCRT or RT...
  101. ncbi Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival
    Dipen M Maru
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1576-85. 2009
    ..It was unclear whether this difference was due to loss of heterozygosity (LOH) or to other genetic alterations at this locus...